Evidence-Based Medicine Guidelines
Oral Pentasa in the treatment of active Crohn's disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Oral Pentasa in the Treatment of Active Crohn's Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn's_disease.
Oral Pentasa in the treatment of active Crohn's disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn's_disease. Accessed December 3, 2023.
Oral Pentasa in the treatment of active Crohn's disease. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn's_disease
Oral Pentasa in the Treatment of Active Crohn's Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2023 December 03]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn's_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Oral Pentasa in the treatment of active Crohn's disease
ID - 454565
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/454565/all/Oral_Pentasa_in_the_treatment_of_active_Crohn's_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
